Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-12-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Treatment with liver cell infusion for children with urea cycle disorders (UCD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Heterologous Liver Cells for Infusion in Children With Urea Cycle Disorders

NCT00718627

Urea Cycle Disorders Carbamoylphosphate Synthetase I Deficiency Ornithine Transcarbamylase Deficiency +1 more

COMPLETED PHASE2

Hepatic Histopathology in Urea Cycle Disorders

NCT04908319

Citrullinemia 1 ARGI Deficiency ASL Deficiency +7 more

RECRUITING

Study of Tauroursodeoxycholic Acid for Hepatobiliary Disease in Cystic Fibrosis

NCT00004441

Cystic Fibrosis

COMPLETED NA

Study of Bile Acids in Patients With Peroxisomal Disorders

NCT00004442

Infantile Refsum's Disease Zellweger Syndrome Bifunctional Enzyme Deficiency +1 more

TERMINATED NA

Safety and Efficacy Study of Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis

NCT01088607

Primary Sclerosing Cholangitis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Urea cycle disorders are rare inherited diseases that generally have a poor outcome, especially with onset of the disease in the neonatal period. UCDs are caused by a deficiency of one of six enzymes responsible for removing ammonia from the bloodstream. Instead of being converted into urea which is removed from the body with the urine, ammonia accumulates in UCD patients leading to brain damage or death. In the light of a mortality rate of \> 50% at the age of 10 years the current pharmacological and dietary therapy is of modest success. Furthermore, mental retardation, cerebral palsy and other neurological sequelae are common among surviving patients.

In the last years, orthotopic liver transplantation (OLT) has become the best therapeutic option for UCD with long-term survival rates of about 90%. However, in the first weeks of life OLT still is technically demanding and prone to complications. With larger size of the recipient, the technical problems with OLT decrease considerably. The increased body weight usually achieved at the age of more than 8 weeks is related to a major reduction in transplantation related morbidity. Stabilization of metabolism until the patient can undergo OLT is essential.

In this study, young children with UCD will be treated by repetitive application of human liver cells. In the last consequence, the aim of this new therapy option is to supply a sufficient amount of healthy liver cells to compensate for the metabolic defect and to reduce the risk of neurological deterioration while awaiting OLT.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urea Cycle Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Liver Cell Infusion

Group Type EXPERIMENTAL

HHLivC

Intervention Type BIOLOGICAL

multiple infusion of liver cells

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HHLivC

multiple infusion of liver cells

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: birth up to 5 years of age
* Ornithine transcarbamylase deficiency \[OTCD\], Carbamyl phosphate synthetase I deficiency \[CPSD\], Argininosuccinate synthetase deficiency \[ASSD, Citrullinaemia\]
* Written Informed Consent

Exclusion Criteria

* Weight ≤ 3.5 kg
* Presence of acute infection at the time of inclusion
* Severe chronic or systemic disease other than study indication
* Structural liver disease (eg, cirrhosis, portal hypertension)
* Required valproate therapy

Minimum Eligible Age

1 Day

Maximum Eligible Age

5 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No